Announcements Trials
Browse Landscape

Phase

Phase 1 11Phase 2 8Phase 3 5Phase 1/2 5

Status

Active not recruiting 3Terminated 1Completed 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1Breast 1

Conditions

Ovarian Neoplasms 2mCRPC 1Prostatic Neoplasms 1Fallopian Tube Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × talazoparib × Clear all
NCT03395197 2026-04-22

TALAPRO-2

Pfizer

Phase 3 Active not recruiting
1,054 enrolled 21 charts 1 FDA

mCRPC

NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Pfizer

Phase 3 Active not recruiting
68 enrolled
Gynecologic

Ovarian Neoplasms

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Pfizer

Phase 3 Active not recruiting
599 enrolled
Genitourinary

Prostatic Neoplasms

NCT03642132 2023-04-06

JAVELIN OVARIAN PARP100

Pfizer

Phase 3 Terminated
79 enrolled 18 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01945775 2022-01-20

EMBRACA

Pfizer

Phase 3 Completed
431 enrolled 23 charts 1 FDA
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡